Veeva, Revolution Medicines, Pulse Biosciences flagged as overbought
Veeva Systems reported better-than-expected second-quarter results and raised FY27 guidance above estimates, while Revolution Medicines said the FDA approved Rasonque for metastatic pancreatic adenocarcinoma. Pulse Biosciences was added to a bullish analyst call.
As of Aug. 27, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term.
An asset is typically considered overbought when the RSI is above 70, according to Pro. Here’s the latest list of major overbought players in this sector. Veeva Systems Inc (NYSE: VEEV ) On Aug. 26, Veeva Systems reported better-than-expected second-quarter financial results and raised its FY27 guidance above estimates.
“AI is opening up the next big chapter for Veeva and life sciences,” said CEO Peter Gassner. “Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. 50. 91 on Wednesday.
93. Revolution Medicines Inc (NASDAQ: RVMD ) On Aug. S. Food and Drug Administration (FDA) on Wednesday approved Revolution Medicines’ Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma (PDAC).
“The FDA approval of RASONQUE is a monumental step forward for patients with pancreatic cancer and for the oncology field,” said Mark A. , chief executive officer and chairman of Revolution Medicines. 30. 44 on Wednesday.
Pulse Biosciences Inc (NASDAQ: PLSE ) On Aug. 17, Needham analyst Mike Matson initiated coverage on Pulse Biosciences with a Buy rating and announced a price target of $58. 90. 10 on Wednesday.
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare. Photo via Shutterstock